• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    uniQure N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/9/25 7:13:06 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QURE alert in real time by email
    000159056000-0000000false00015905602025-05-092025-05-09

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    ​

    FORM 8-K

    ​

    CURRENT REPORT

    ​

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    ​

    Date of Report (Date of earliest event reported): May 9, 2025

    ​

    uniQure N.V.

    (Exact Name of Registrant as Specified in Charter)

    ​

    The Netherlands

      

    001-36294

      

    N/A

    (State or Other
    Jurisdiction of Incorporation)

    (Commission
    File Number)

    (IRS Employer
    Identification No.)

    ​

    Paasheuvelweg 25a,
    1105 BP Amsterdam, The Netherlands

      

    N/A

    (Address of Principal Executive Offices)

    (Zip Code)

    ​

    Registrant’s telephone number, including area code: +31-20-566-7394

    ​

    (Former Name or Former Address, if Changed Since Last Report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ​

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ​

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ​

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ​

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class:

      

    Trading Symbol(s)

      

    Name of each exchange on which registered:

    Ordinary Shares, par value €0.05 per share

    QURE

    The Nasdaq Stock Market LLC
    The Nasdaq Global Select Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    ​

    Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    Item 2.02

    Results of Operations and Financial Condition.

    ​

    On May 9, 2025, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025 and highlighting Company progress. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    ​

    The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

    ​

    ​

    ​

    Item 9.01 Financial Statements and Exhibits.

    ​

    (d) Exhibits.

    ​

    ​

    Exhibit No.

        

    Description

    ​

    ​

    ​

    99.1

    ​

    Press Release of uniQure N.V. dated May 9, 2025

    ​

    ​

    ​

    104

    ​

    Cover Page Interactive Data File (embedded with the Inline XBRL document).

    ​

    ​

    ​

    ​

    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

    ​

     

    UNIQURE N.V.

     

     

     

     

     

    Date: May 9, 2025

    By:

    /s/ JEANNETTE POTTS

     

     

    Jeannette Potts

     

     

    Chief Legal and Compliance Officer

    ​

    ​

    Get the next $QURE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QURE

    DatePrice TargetRatingAnalyst
    4/1/2025$38.00Buy
    Chardan Capital Markets
    12/10/2024Outperform → Strong Buy
    Raymond James
    10/10/2024$20.00Outperform
    Raymond James
    2/29/2024$8.00Buy → Neutral
    Goldman
    12/19/2023$52.00 → $10.00Buy → Neutral
    Mizuho
    3/17/2022$40.00Neutral → Buy
    UBS
    12/17/2021$75.00 → $58.00Strong Buy → Outperform
    Raymond James
    10/27/2021$66.00Outperform
    William Blair
    More analyst ratings

    $QURE
    Financials

    Live finance-specific insights

    See more
    • uniQure to Announce First Quarter 2025 Financial Results

      LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first quarter 2025 financial results before market open on Friday, May 9, 2025. Management will then host a conference call at 8:30 a.m. ET. As the Company advances its pipeline and AMT-130 toward a BLA submission and potential commercialization, uniQure is initiating quarterly earnings calls to provide regular updates on progress and to enhance engagement with the investment community. The event will be webcast under the Events & Presentations section of uniQure's

      5/5/25 4:05:00 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

      ~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval ~ ~ FDA agrees that the composite Unified Huntington's Disease Rating Scale (cUHDRS) may serve as an intermediate clinical endpoint for Accelerated Approval ~         ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Dec. 10, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company reached agreement

      12/10/24 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease

      ~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the composite Unified Huntington's Disease Rating Scale (cUHDRS) at 24 months compared to a propensity score-weighted external control ~ ~ Achieved statistically significant lowering of CSF neurofilament light protein (NfL) compared to baseline at 24 months in patients treated with AMT-130; Mean CSF NfL levels for both doses were below baseline at 24 months ~ ~ Granted first-ever Regenerative Medicine Advanced Therapy (RMAT) designation in Huntington's disease; uniQure expects to meet with the FDA in t

      7/9/24 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    SEC Filings

    See more
    • SEC Form 10-Q filed by uniQure N.V.

      10-Q - uniQure N.V. (0001590560) (Filer)

      5/9/25 7:40:19 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - uniQure N.V. (0001590560) (Filer)

      5/9/25 7:13:06 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by uniQure N.V.

      DEFA14A - uniQure N.V. (0001590560) (Filer)

      4/28/25 6:03:12 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

      ~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~ ~ Held Type B FDA meetings in the first and second quarters of 2025 to advance BLA preparations for AMT-130; regulatory update expected in the second quarter of 2025 ~ ~ AMT-260 clinical data from first patient to be presented at Epilepsy Therapies & Diagnostics Development Symposium on May 29, 2025 ~ ~ Cash, cash equivalents and current investment securities of approximately $409.0 million as of March 31, 2025 expected to fund operations into second half o

      5/9/25 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure to Announce First Quarter 2025 Financial Results

      LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first quarter 2025 financial results before market open on Friday, May 9, 2025. Management will then host a conference call at 8:30 a.m. ET. As the Company advances its pipeline and AMT-130 toward a BLA submission and potential commercialization, uniQure is initiating quarterly earnings calls to provide regular updates on progress and to enhance engagement with the investment community. The event will be webcast under the Events & Presentations section of uniQure's

      5/5/25 4:05:00 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

      ~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ ~ Additional regulatory update and guidance on the Biologics License Application submission expected in the second quarter of 2025 ~ LEXINGTON, Mass. and AMSTERDAM, April 17, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to AMT-130 for the treatment of Huntington's disease, a rare, inherited neurodegenerative disorder for which the

      4/17/25 7:17:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets resumed coverage on uniQure with a new price target

      Chardan Capital Markets resumed coverage of uniQure with a rating of Buy and set a new price target of $38.00

      4/1/25 8:05:22 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure upgraded by Raymond James

      Raymond James upgraded uniQure from Outperform to Strong Buy

      12/10/24 11:36:55 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on uniQure with a new price target

      Raymond James resumed coverage of uniQure with a rating of Outperform and set a new price target of $20.00

      10/10/24 8:37:20 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by uniQure N.V.

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      11/14/24 12:01:42 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by uniQure N.V.

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      11/13/24 4:05:14 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by uniQure N.V.

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      10/25/24 9:48:27 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO, Managing Director Kapusta Matthew C was granted 99,000 units of Ordinary Shares and sold $291,629 worth of Ordinary Shares (28,341 units at $10.29), increasing direct ownership by 12% to 651,454 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      3/5/25 5:32:51 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Abi-Saab Walid was granted 38,000 units of Ordinary Shares and sold $13,891 worth of Ordinary Shares (1,350 units at $10.29), increasing direct ownership by 32% to 151,903 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      3/5/25 5:28:57 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Klemt Christian was granted 73,000 units of Ordinary Shares and sold $107,407 worth of Ordinary Shares (10,438 units at $10.29), increasing direct ownership by 40% to 217,730 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      3/5/25 5:25:33 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    Leadership Updates

    Live Leadership Updates

    See more
    • uniQure Announces Leadership Addition to Support Advancement of Clinical Programs

      LEXINGTON, Mass. and AMSTERDAM, June 26, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Walid Abi-Saab, M.D., as Chief Medical Officer, effective immediately. He will report to Matt Kapusta, Chief Executive Officer of uniQure, and will be based in the Company's Basel, Switzerland office. Dr. Abi-Saab will be responsible for leading all clinical research and development, regulatory affairs, medical affairs, and program management at uniQure. With Dr. Abi-Saab's appointment, Dr. Ricardo Dolmetsch becomes President and Chief Scientific Officer. He

      6/26/23 7:11:42 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VectorY Appoints Sander van Deventer as CEO and Makes Key Appointments to Its Leadership Team

      Sander van Deventer is co-founder and former Chief Technology Officer of the Company Elena Ritsou assumes role of Chief Corporate Officer Barbara Sanders is promoted to Chief Technology Officer Industry veteran Frank Walsh joins as an Independent Board Member VectorY Therapeutics, a biotech company developing innovative vectorized antibody approaches for the treatment of neurodegenerative diseases, today announces the appointment of Sander van Deventer, co-founder and formerly Chief Technology Officer, as Chief Executive Officer. The Company has also made key appointments to its leadership team. Sander van Deventer has 25 years of experience in drug development and a longstanding

      11/8/22 4:00:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genespire appoints Dr. Sabah Sallah as Chief Medical Officer

      Genespire appoints Dr. Sabah Sallah as Chief Medical Officer Accomplished executive with extensive preclinical and clinical gene therapy experience joins Genespire to accelerate pipeline to the clinic Milan, Italy, 7 July 2022: Genespire, a next generation gene therapy company developing first-in-class transformative therapies with advanced lentiviral vectors, today announces the appointment of Dr. Sabah Sallah MD, PhD as Chief Medical Officer. Dr. Sallah will lead the Company's clinical strategy, development and operations as Genespire progresses its novel advanced lentiviral gene therapy platforms towards the clinic. Dr. Sallah is a board-certified hematologist who has spent more than

      7/7/22 2:00:00 AM ET
      $FRLN
      $QURE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations